Nateglinide

DEA Class; Rx

Common Brand Names; Starlix

  • Antidiabetics, Meglitinides Derivatives

Meglitinide oral hypoglycemic agent; stimulates insulin secretion
Rapid onset and short duration of action replicates physiological insulin profiles around meals
Used prior to meals for the treatment of type 2 diabetes mellitus in adults; not commonly used as monotherapy

Indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise.

Not for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis

Documented hypersensitivity

Increased uric acid (10%)

Dizziness (4%)

Arthropathy (3%)

Flu-like syndrome

Weight gain

Hypoglycemia (2%)

Diarrhea

Nausea

Not to be used in combination with an insulin secretagogue (eg, glyburide)

Not to be used as substitute for metformin monotherapy but as adjunctive

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with therapy

Available data from published literature and applicant’s pharmacovigilance in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes

There are no data on presence of nateglinide in human milk, effects on breastfeeding infant, or on milk production

Adults

360 mg/day PO.

Elderly

360 mg/day PO.

Adolescents

Safety and efficacy have not been established.

Children

Safety and efficacy have not been established.

Nateglinide

tablet

  • 60mg
  • 120mg

About the Author

You may also like these

0